G
ermline RUNX1 mutations lead to thrombocytopenia and platelet dysfunction in familial platelet disorder with predisposition to acute myelogenous leukemia (AML). Multiple aspects of platelet function are impaired in these patients, associated with altered expression of genes regulated by RUNX1. We aimed to identify RUNX1-targets involved in platelet function by combining transcriptome analysis of patient and shRUNX1-transduced megakaryocytes (MK). Down-regulated genes included TREM-like transcript (TLT)-1 (TREML1) and the integrin subunit alpha (α)-2 (ITGA2) of collagen receptor α2-beta (b)-1, which are involved in platelet aggregation and adhesion, respectively. RUNX1 binding to regions enriched for H3K27Ac marks was demonstrated for both genes using chromatin immunoprecipitation. Cloning of these regions upstream of the respective promoters in lentivirus allowing mCherry reporter expression showed that RUNX1 positively regulates TREML1 and ITGA2, and this regulation was abrogated after deletion of RUNX1 sites. TLT-1 content was reduced in patient MK and platelets. A blocking anti-TLT-1 antibody was able to block aggregation of normal but not patient platelets, whereas recombinant soluble TLT-1 potentiated fibrinogen binding to patient platelets, pointing to a role for TLT-1 deficiency in the platelet function defect. Low levels of α2 integrin subunit were demonstrated in patient platelets and MK, coupled with reduced platelet and MK adhesion to collagen, both under static and flow conditions. In conclusion, we show that gene expression profiling of RUNX1 knock-down or mutated MK provides a suitable approach to identify novel RUNX1 targets, among which downregulation of TREML1 and ITGA2 clearly contribute to the platelet phenotype of familial platelet disorder with predisposition to AML.
Downregulation of TREM-like transcript-1 and collagen receptor α2 subunit, two novel RUNX1-targets, contributes to platelet dysfunction in familial platelet disorder with predisposition to acute myelogenous leukemia Introduction
The transcription factor RUNX1 is a key regulator of the megakaryocytic lineage, where it participates in a complex transcriptional network co-ordinating platelet biogenesis and function.
1,2 RUNX1 co-operates with other transcriptional regulators, including GATA-1, FLI-1 and SCL at megakaryocyte (MK)-specific promoters, 1 whereas co-occupancy of RUNX1 with FLI-1 and NF-E2 has been shown to prime the late MK program. 3 Conditional RUNX1 inactivation in mice leads to MK maturation arrest and a substantial decline in platelet counts, highlighting the key role of RUNX1 as a master regulator of the MK lineage. 4 Germline RUNX1 mutations in humans underlie familial platelet disorder with predisposition to acute myelogenous leukemia (FPD/AML), which is characterized by thrombocytopenia, platelet dysfunction, and a lifelong 30-50% predisposition to hematologic malignancies, including myeloid and lymphoid neoplasms.
5
RUNX1 mutations exerting dominant-negative effects over the wild-type (WT) protein are associated with a higher leukemic rate than those acting via haploinsufficiency, 6 whereas no differences in the severity of the platelet phenotype are seen between both types of mutations. 7 Although once considered a rare condition, FPD/AML is now diagnosed at increasing frequency due to heightened diagnostic awareness during the workup of individuals presenting with thrombocytopenia of uncertain etiology or hereditary myeloid malignancies.
The platelet defect in FPD/AML is complex and includes abnormalities in platelet number and function, which lead to a bleeding diathesis of variable severity, ranging from mild or asymptomatic cases to a severe bleeding tendency. Thrombocytopenia is usually mild to moderate and is caused by impaired platelet production secondary to defects in multiple steps of MK development, including MK differentiation, maturation, polyploidization and proplatelet formation. 2 While marked dysmegakaryopoiesis with a severe defect in proplatelet formation is observed in vitro, the presence of only mild thrombocytopenia, often at the lower limit of normal range, suggests a yet unknown compensatory mechanism in vivo. The platelet function defect is present in most, if not all, patients with FPD/AML and involves multiple abnormalities in platelet structure and activation pathways, including defective platelet aggregation and release, dense granule deficiency, associated in some pedigrees with partial alpha (α)-granule defect, and impaired αIIb-beta (b)-3 (GPIIbIIIa) activation and outside-in signaling. 8, 9 These abnormalities are likely due to altered expression of RUNX1-targets involved in platelet biology. The study of FPD/AML platelet samples has revealed downregulation of several RUNX1-regulated genes. Transcriptome analysis of platelets from one patient showed reduced levels of MYL9, ALOX12, PKCθ, RAB1B and PLDN, 10 whereas dysregulated expression of MPL, 11 MYH10
12
, RAB27B 8 and NF-E2 8 has been identified by a candidate-gene approach in other pedigrees. However, the mechanisms underlying FPD/AML platelet function defect and the effects of RUNX1 mutations on the expression of other potential genes are still not completely understood. In this study, we combined expression profiling of mature shRUNX1-transduced and FPD/AML MK to gain further insight into RUNX1-regulated genes involved in platelet function. Using this approach, we identified triggering receptor expressed on myeloid cells (TREM)-like transcript (TLT)-1 and integrin subunit α2 of collagen receptor α2b1 as two novel RUNX-1 targets, whose expression was decreased in FPD/AML MK and platelets.
Methods

Human samples
Patients from three previously described FPD/AML pedigrees 2, 8, 11 (Table 1 and Online Supplementary Table S1 ), healthy subjects, and individuals after stem cell mobilization were included. At the time of the study, patients had thrombocytopenia and/or platelet dysfunction with no evidence of myelodysplastic or leukemic transformation. Details on experiments performed on each patient are provided in Online Supplementary  Table S2 . The study was approved by the Ethics Committee of INSERM RBM 01-14 for the project "Network on the inherited diseases of platelet function and platelet production" in France and the Ethics Committee of the Instituto de Investigaciones Médicas "Dr. Alfredo Lanari" in Argentina. Patients and controls gave signed informed consent.
Megakaryocyte culture and transcriptome analysis
CD34
+ cells were isolated from cord blood, leukapheresis samples or peripheral blood of patients and healthy subjects using a magnetic cell-sorting system (AutoMACS or MiniMACS, Miltenyi Biotec SAS, Paris, France) and grown in serum free medium 2 or Stem Span medium (StemCell Technologies, Vancouver, BC, Canada), supplemented with 10 ng/mL thrombopoietin (TPO) (Kirin Brewery, Tokyo, Japan or Miltenyi Biotec) and 25 ng/mL Stem Cell Factor (SCF) (Biovitrum AB, Stockholm, Sweden or Miltenyi Biotec). For culture of patient MK, 10 ng/mL IL-6 (Tebu or Miltenyi Biotec), 100 U/mL IL-3 (Novartis or R&D Systems, MN, USA) and 1 ng/mL fetal liver tyrosine kinase 3 ligand (FLT3-L) (Celldex Therapeutics or R&D Systems) were added.
For transcriptome analysis, patient and control MK were cultured as detailed above, stained on day 10 of culture with allophycocyanin (APC)-conjugated anti-CD41 and phycoerythrin (PE)-anti-CD42 antibodies (BD Biosciences, Le Pont de Claix, France), and CD41 + CD42 + were sorted by flow cytometry. CD34 + cells from leukapheresis samples were transduced on days 6 and 7 of culture with lentiviruses encoding shRUNX1_1, shRUNX1_2 and shSCR (control shRNA), and CD41 + CD42 + GFP + cells were sorted on day 10 by flow cytometry, as previously described. 2, 13 RNA was extracted using the RNeasy Micro Kit (Qiagen, France) according to the manufacturer's instructions. Transcriptome analysis was performed using the Agilent Whole Human Genome Microarray (see Online Supplementary Methods).
Statistical analysis
For comparison between patients and controls, MannWhitney test or Wilcoxon matched pairs test were applied. For promoter activity and chromatin immunoprecipitation-polymerase chain reaction (ChIP-PCR) assays, paired t-test was used. For assessment of the effect of a blocking anti-TLT-1 antibody on proplatelet formation, repeated measures ANOVA was used. All statistical analyses were two-sided; P<0.05 was considered significant. The GraphPad Prism 6.01 (La Jolla, CA, USA) software was used for analysis.
Other methods are described in the Online Supplementary Appendix. , between genes deregulated in shRUNX1-transduced MK (shRUNX1_1_A, shRUNX1_1_B and shRUNX1_2), and between genes deregulated in both patient and shRUNX1-transduced MK. (A) A total of 598 genes were up-regulated in patient MK (n=4) and 289 genes were up-regulated in shRUNX1-transduced MK (n=3). A total of 43 genes were found to be up-regulated in both patient and shRUNX1-transduced MK. (B) A total of 492 genes were down-regulated in patient MK (n=4) and 499 genes (527 probes) were down-regulated in shRUNX1-transduced MK (n=3). A total of 61 genes were found to be down-regulated in both patient and shRUNX1-transduced MK. shRUNX1_1 was used in two experiments (shRUNX1_1_A and shRUNX1_1_B) and shRUNX_2 in one. (C) Differentially down-regulated genes and functions associated with different biological processes. Gene ontology (GO) terms and differentially down-regulated genes are represented as nodes based on their kappa score >0.4. The node size represents the GO terms enrichment significance. (D) Microarray data for ITGA2 and TREML1 in MK from patients (AII-1 and AII-2, carrying the R174Q mutation, and BII-2 and BIII-1, with the R139X mutation) relative to healthy subjects (n=4) (horizontal dashed line). 
Results
Gene expression profiling of shRUNX1-transduced and familial platelet disorder with predisposition to acute myelogenous leukemia megakaryocytes reveals downregulation of TREML1 and ITGA2
To identify RUNX1-targets that could be involved in FPD/AML platelet dysfunction, we first performed transcriptome analysis of mature (CD41 + CD42 + ) MK cultured from four patients, two carrying the R174Q mutation, and two with the R139X mutation. We then analyzed the transcriptome of MK cultured from normal leukapheresisderived CD34 + cells transduced with shRUNX1 at days 6 and 7 of culture in order to detect RUNX1 targets involved in late stages of MK differentiation and, more particularly, in proplatelet formation and platelet function. A significant increase in 43 genes and a decrease in 61 genes was shown in both FPD/AML and shRUNX1-transduced MK ( Figure 1A and B and Online Supplementary Table S3A-F). Analysis of up-regulated genes did not show any potential candidates for FPD/AML platelet dysfunction (Online Supplementary Table S4A and Online Supplementary Figure  S1 ). In contrast, analysis of GO pathways revealed two down-regulated genes, TREML1 and ITGA2, that were of interest regarding their role in platelet biology ( Figure 1C and D and Online Supplementary Table S4B) .
TREML1 codes for TLT-1, which represents an immunoreceptor tyrosine-based inhibition motif (ITIM)-containing receptor exclusively expressed in MK and platelets, where it is stored in α-granules.
14 It undergoes surface translocation upon platelet activation 14 and has been recently proposed to represent a more rapid and sensitive marker of platelet activation compared to P-selectin. 15 TLT-1 ectodomain is released following platelet activation, leading to a naturally occurring soluble fragment (sTLT-1), which represents an abundant constituent of the platelet sheddome. 16 Unlike other platelet ITIM receptors, the non-canonical TLT-1 has activating effects. 17 Early work showed that, in a transiently transfected RBL-2H3 cell line, TLT-1 acts as a co-stimulatory receptor enhancing FceRI-mediated calcium signaling through recruitment of Src homology 2 domain-containing tyrosine phosphatase (SHP)-2 to its cytoplasmic ITIM domain. 18 In human platelets, incubation with a blocking anti-TLT-1 antibody was shown to inhibit platelet aggregation triggered by thrombin, 19 whereas, conversely, sTLT-1 enhances platelet aggregation triggered by a variety of classic platelet agonists. 17 Fibrinogen represents the only known ligand for TLT-1 and has been shown to bind both the full-length protein as well as the soluble form, 17 and to favor fibrinogen deposition in vivo in a murine model of acute lung injury. 20 Although the precise mechanism of TLT-1 action still has to be clearly defined, it has been proposed that, during platelet aggregation, fibrinogen is cross-linked by TLT-1, facilitating platelet-fibrinogen interactions and higher-order platelet aggregates, in concert with GPIIbIIIa. 17 In addition, TLT-1 has been shown to interact through its cytoplasmic domain with ERM (ezrin/radixin/moesin) proteins, potentially linking fibrinogen to the platelet cytoskeleton. 17 The essential role of TLT-1 in platelet function is revealed in Treml1 -/-mice, which display mild thrombocytopenia, decreased platelet aggregation, and prolonged bleeding time. 17 In addition to its role in hemostasis, sTLT-1 released by platelets reduces inflammation and organ damage during sepsis by counteracting leukocyte activation and platelet-neutrophil crosstalk.
21
ITGA2 encodes the α2 subunit of collagen receptor α2b1, which, in concert with GPVI, mediates the plateletcollagen interaction at sites of vascular injury required for stable platelet adhesion. 22 Integrin α2b1 is essential when platelets are exposed to monomeric collagen, whereas it plays a supportive role for fibrillar collagen, where GPVI is the central receptor. The complementary interplay between both collagen receptors is required for an optimal platelet response to collagen. Upregulation of ITGA2 was demonstrated in K562 cells transduced with a RUNX1 expression vector, suggesting RUNX1 may regulate ITGA2 expression. 23 Thus, we next assessed TREML1 and ITGA2 expression profile during in vitro megakaryopoiesis and showed that TREML1 and ITGA2 mRNA levels increase during normal MK differentiation ( Figure 1E ). Using real-time PCR, we confirmed that TREML1 and ITGA2 mRNAs are decreased in mature MK after shRNA-mediated RUNX1 inhibition ( Figure 1F ). Moreover, transduction of a WT RUNX1 cDNA carrying a mutation that does not change the amino acid sequence but prevents its recognition by shRUNX1 (RUNX1 mut ) was able to rescue the inhibition in TREML1 and ITGA2 induced by shRUNX1 ( Figure 1G ), further demonstrating the relationship between RUNX1 and both TREML1 and ITGA2.
Low TLT-1 and collagen receptor α2 in FPD/AML haematologica | 2019; 104 (6) 1247 To investigate whether TREML1 and ITGA2 represent direct RUNX1 targets, we searched for RUNX1 and activating histone mark H3K27Ac enrichment across the entirety of these two genes by ChIP-sequencing in mature MK. Although no significant RUNX1 enrichment was shown in promoter regions, it was detected in intronic regions of both genes (Figure 2A and C) . RUNX1 putative binding sites overlapping H3K27Ac were then identified by in silico analysis. Using ChIP, we confirmed 3-4-fold enrichment for RUNX1 in two RUNX1 sites identified in TREML1 and more than 5-fold enrichment in four sites identified in ITGA2 (Figure 2B and D) . To assess whether these sites are functional, we cloned these intragenic regulatory regions (TREML1_RR and ITGA2_RR) upstream of TREML1 and ITGA2 promoters into lentivirus allowing mCherry reporter expression under these promoters (Online Supplementary Figure S2A and B) and tested them in A.C. Glembotsky et al.
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mature MK. Expression of mCherry fluorescent protein increased in both cases when TREML1_RR and ITGA2_RR were cloned upstream of the respective promoters and significantly decreased after specific deletion of RUNX1 binding sites ( Figure 2E and F) . These results clearly demonstrate that the identified sites are functional in mature MK and that TREML1 and ITGA2 are direct RUNX1 targets positively regulated by this transcription factor. mCherry reporter expression driven by TREML1_RR and ITGA2_RR harboring deleted RUNX1 sites did not reach the same level as for promoters alone, especially for ITGA2; this is probably because RUNX1 cooperates with other transcription factors. Indeed, ETS and EVI1 binding sites and EVI1, SCL and ETS sites are identified in TREML1_RR and ITGA2_RR regions, respectively. Moreover, at least one other site positive for H3K27Ac mark binds RUNX1 at position 52362118-52362307nt ( Figure 2C ). This site could also be involved in the regulation of ITGA2 by RUNX1.
TLT-1 is decreased in platelets and megakaryocytes in familial platelet disorder with predisposition to acute myelogenous leukemia
Considering that the main role of TLT-1 is related to platelet function, we next assessed the levels in platelets. First, we showed decreased TREML1 transcripts by qPCR Low TLT-1 and collagen receptor α2 in FPD/AML haematologica | 2019; 104 (6) 1249 Figure 3A) . Western blot analysis of platelet samples confirmed a marked decrease in TLT-1 content ( Figure 3B ), revealing for the first time downregulation of a member of the family of ITIM-bearing receptors in patients with RUNX1 mutations. We have previously shown that patients from this pedigree display partial deficiency of α-granules, 8 where TLT-1 is located, and this finding was associated with a mild decrease in α-granule protein TSP-1. 8 Heterogeneous platelet content of other α-granule proteins was demonstrated by other authors, including reduced levels of PF4, which is regulated by RUNX1, 24 and preserved levels of b-TG and PDGF. 25 More recently, RUNX1 deficiency has been linked to abnormal ER-to-Golgi trafficking and protein sorting leading to low von Willebrand factor (vWF) α-granule content. 26 Although down-regulated TREML1 gene expression secondary to RUNX1 loss-of-function seems to be the major mechanism leading to the low TLT-1 found in this study, we cannot exclude the possibility that α-granule defects could contribute in part to the profound reduction in TLT-1 protein.
Whereas incubation of normal platelets with a blocking anti-TLT-1 antibody inhibited thrombin-induced platelet aggregation, as previously reported, 19 it had no effect on thrombin-induced aggregation of FPD/AML platelets ( Figure 3C ), further demonstrating the absence of relevant amounts of TLT-1 in patient platelets. Conversely, consistent with the functional role of sTLT-1 in platelet activation, 17 and as previously shown for platelet adhesion and actin polymerization on fibrinogen matrices, 27 a recombinant soluble fragment (rsTLT-1) was able to potentiate thrombin-induced fibrinogen binding to normal platelets ( Figure 3D ). In the absence of rsTLT-1, thrombin-induced fibrinogen binding was lower in patients from pedigree D compared to controls, as previously reported. 8 This defect was partially corrected by incubation of patient platelets with rsTLT-1 ( Figure 3D ), pointing to a role for TLT-1 deficiency in the platelet function defect. However, several other abnormalities are also involved, possibly contributing to the variability in platelet aggregation tests among patients ( Table 1) .
As shown in this work, TREML1 gene expression levels are low in normal early megakaryopoiesis and increase markedly along MK maturation reaching higher expression levels in mature MK. Double immunofluorescence labeling of TLT-1 and vWF in mature (CD41 + CD42 + ) MK from one control and 2 patients (DII-1 and DIII-3) confirmed that TLT-1 is mainly localized in α-granules (Figure 4) , as previously reported.
14 However, part of TLT-1 does not co-localize with vWF and is present in a different subpopulation of α-granules. Interestingly, a distinct staining pattern of TLT-1 and P-selectin was recently shown in mouse and human platelets and mouse MK, suggesting differential compartmentalization of these proteins within α-granules, 15 as previously shown for other proteins packaged in platelets. 28 TLT-1-positive granules were less abundant or absent in patient compared to control MK (Figure 4) .
The role of TLT-1 in normal MK is not known. TLT-1-deficient mice display a 20% decrease in platelet counts, 17 although the underlying mechanism has not been explored. In order to gain insight into this, we incubated human cord blood or leukapheresis-derived MK with a blocking anti-TLT-1 antibody or a control IgG. There was no significant difference in megakaryocyte output and maturation in the presence of anti-TLT-1 compared to control, whereas proplatelet formation was reduced (Online Supplementary Figure S3) , suggesting TLT-1 may have a role in normal proplatelet formation. However, further study will be required to definitively establish this issue and to determine whether TLT-1 deficiency contributes to defective platelet production in FPD/AML.
Levels of integrin subunit α2 and collagen adhesion are decreased in platelets in familial platelet disorder with predisposition to acute myelogenous leukemia
Transcript levels of ITGA2, coding for the α2 integrin subunit of collagen receptor α2b1, were also shown to be decreased in platelets from pedigree D by qPCR ( Figure  5A ). Accordingly, surface expression of α2 (GPIa) was substantially reduced, as revealed by analysis of platelet-rich plasma ( Figure 5B ) and whole blood flow cytometry (Online Supplementary Table S5) , and further confirmed by western blot ( Figure 5C ). The reduction in surface α2 was associated with a decrease in platelet surface expression of the heterodimeric b1 subunit (GPIIa), whereas GPVI, GPIIbIIIa, GPIb-IX were preserved (Table 2) , indicating a selective abnormality in the α2b1 complex. The reduction in b1 is probably due to the concomitant decrease in its α2 partner, as b1 subunit (ITGB1) mRNA levels were preserved (Online Supplementary Figure S4 ). In addition, platelet surface levels of α5 and α6 integrin subunits, which also heterodimerize with b1, were normal or in the lower normal limit (Table 2) .
A.C. Glembotsky et al.
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haematologica | 2019; 104(6) GPIIa represents the b1 integrin subunit of the collagen receptor α2b1. Relative fluorescence intensity (RFI) was calculated as the ratio between the corresponding antibody and the isotypic control. Results are expressed as the ratio between RFI in each patient and a simultaneously assayed control sample. The reference range was established by the Mean ± two Standard Deviations of ten healthy subjects who were simultaneously studied. Low α2b1 has been described in ANKRD26-related thrombocytopenia (RT), 29 which shares several features with FPD/AML. However, whereas we confirmed that reduced α2 was restricted to some but not all ANKRD26-RT patients (Online Supplementary Figure S5 ), all FPD/AML patients studied showed this defect. Interestingly, α2 deficiency was recently reported in two other FPD/AML pedigrees. 30, 31 Study of a larger cohort is required to determine whether low α2 is a constant feature of FPD/AML and could be useful as a screening tool in this setting.
Consistent with the essential role of α2b1 in platelet interaction with monomeric collagen I, 22, 32 adhesion to this substrate was severely impaired ( Figure  5D and E). Moreover, platelet adhesion was also, albeit less markedly, reduced over fibrillar collagen I ( Figure 5D and E). Considering that GPVI, which has a more prominent role over fibrillar collagen, was preserved, other abnormalities in FPD/AML platelets may contribute to defective adhesion to fibrillar collagen in addition to low α2b1. In contrast, platelet adhesion to convulxin, which relies on GPVI, and to fibrinogen, which depends mainly on GPIIbIIIa, were largely preserved (Online Supplementary  Table S6 ). As an approach to mimic the in vivo conditions, we studied platelet aggregate formation under flow, which revealed a substantial decrease in surface area coverage over a collagen substrate for patient compared to control platelets ( Figure 5F and G). Overall, these abnormalities suggest that primary hemostasis might be impaired in FPD/AML, although the clinical relevance of this finding still has to be determined. On the other hand, defective collagen-induced aggregation (Table 1 ) cannot be explained only by decreased α2b1, as collagen preparations used in aggregometry depend mainly on GPVI. Given this, the aggregation defect in response to collagen and other platelet agonists may also rely on the role played by TLT-1 in fibrinogen binding, platelet aggregate formation and stabilization.
Megakaryocytes in familial platelet disorder with predisposition to acute myelogenous leukemia display low levels of α2 integrin subunit and decreased adhesion to collagen I Platelet production is a tightly regulated process governed by the close interaction between MK and bone marrow (BM) extracellular matrix (ECM) proteins. In addition to its abundance at the vascular bed, collagen I is a crucial component of the BM ECM. MK-collagen I interaction is of critical importance in restraining proplatelet formation at the osteoblastic niche, thus preventing premature platelet release into the interstitial space and allowing normal platelet production into the lumen of BM sinusoids. 33 Ligation of the α2b1 receptor in MK is required for stress fiber formation and adhesion over collagen I, as shown in both human and mouse MK, 33, 34 whereas although α2b1 integrin is involved in collagen I-induced inhibition of proplatelet formation in human MK, 33 it does not seem to be essential in mouse MK, where GPVI mediates the inhibitory signal. 34 Considering the key function of α2b1 in MK behavior over collagen, we next studied MK α2 surface expression and found decreased levels on patient mature (CD41 + CD42 + ) MK ( Figure 6A ). There was a trend towards reduced MK (CD41 + ) adhesion to fibrillar type I collagen, which was confirmed after sorting the mature (CD41 + CD42 + ) MK population, whereas adhesion to fibrinogen was preserved ( Figure 6B and C) . In addition to low α2 levels, other defects in FPD/AML MK could contribute to reduced collagen adhesion. Virtual absence of proplatelet formation from patient cells 2 prevented us from assessing whether physiological collagen I-inhibition in thrombopoiesis was affected. The role of α2b1 in platelet production in vivo remains controversial as, unexpectedly, Itga2
-/-mice show normal platelet counts. 32 Increased MK numbers found in these mice may represent a compensatory mechanism and provide an explanation for the absence of thrombocytopenia in this model. We have previously shown that FPD/AML patients show decreased MK output from hematopoietic progenitors, delayed MK maturation, and low ploidy levels. 2 On this basis, it seems reasonable to consider the possibility that, in vivo, FPD/AML MK may not be able to fully compensate for the decrease in α2 and, in this scenario, α2 downregulation could possibly contribute to impaired platelet production in patients in addition to the above-mentioned MK abnormalities.
Considering that FPD/AML is a heterogeneous condition, study of additional pedigrees would be useful to determine whether patients harboring RUNX1 mutations different from those included in this study display similar defects.
In conclusion, gene expression analysis of RUNX1 knock-down or mutated MK proved to be a suitable approach to identify novel RUNX1 targets involved in platelet biology. TREML1 and ITGA2 may now be added to the growing list of genes regulated by RUNX1 in the megakaryocytic lineage. Down-regulated expression of these genes in patients contributes to the platelet defects induced by RUNX1 mutations. These findings highlight the key role of RUNX1 as a master regulator of the MK lineage, where it modulates the expression of a diverse array of genes crucial to platelet production and function. They also help further unravel the molecular mechanisms underlying the FPD/AML phenotype. 
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